Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

Overview of attention for article published in Frontiers in immunology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 51,932 followers.

#Serplulimab Plus #Chemotherapy As First-Line Treatment For Extensive-Stage #Small_Cell_Lung_Cancer : A Cost-Effectiveness Analysis. ¿ Posible Nuevo Tratamiento de Pacientes en Primera Línea? https://t.co/T3Gi7V4Tqb #lungcancer #roche #AstraZeneca #ibex @A

06 Jan 2023

Reply Repost Favourite

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis https://t.co/DqyOeKG2OT https://t.co/SMtnIH5ZP4

06 Jan 2023

Reply Repost Favourite

New Research: Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis: Introduction The ASTRUM-005 trial (NCT04063163) revealed that combination serplulimab plus… https://t.co/AoStq3G

04 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.